Organon Launches New Fertility Journey Website As Part Of Continuing Commitment To Help Meet The Needs Of Women


JERSEY CITY, NJ – (COMMERCIAL THREAD) – Organon (NYSE: OGN) today announced the launch of a new website – Fertility Journey – that helps educate and empower people with the resources and information needed to navigate the process of caring for fertility. The website aims to meet people wherever they are in their fertility journey and provide them with knowledge and questions to consider to feel prepared and empowered along their journey.

“Infertility is a significant public health problem in the United States Although the problem affects both men and women, the burden of treatment typically falls on women, with 7.3 million women reporting having used infertility services. ‘infertility in the United States between 2006 and 2010,’ said Dr. Barbara Stegmann, Clinical Manager of Women’s Health for Organon. “We want to provide support to anyone wishing to start a family and to those who accompany them. I am proud to work at Organon where we are truly dedicated to understanding the journey.

Every fertility journey is personal, but many on this road have similar questions. When you visit the Organon Fertility Journey website, you can access resources and information, including:

  • Information to understand what can cause infertility and the many factors that can contribute to it in men and women

  • What to expect from the first fertility visit, how to best prepare for this appointment – including questions to consider

  • A description of any clinical tests or evaluations that can be conducted to help identify an individualized fertility treatment plan and ways to navigate the associated cost and coverage options

  • Help prepare for emotional and physical challenges that may arise

“At Organon, we listen fully to their needs and are committed to championing care by creating options built around those needs, ”said Mike Pohleven, US Fertility Manager at Organon. “This launch marks a key milestone in our mission to improve fertility education and provide resources to help people along their fertility journey, and reiterates our commitment to be a source of information for women. and their care team. ”

The website launch is in tandem with the 77e American Society for Reproductive Medicine (ASRM) Scientific Congress and Exhibition in Baltimore, MD (October 17-20) where Organon will participate in fertility conversations and discuss their current fertility products.

About Organon

Organon is a global healthcare company formed by a spin-off of Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lifespan. life. Here for its health, the company has a portfolio of more than 60 drugs and products in a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and a stable established drug franchise, Organon’s products generate strong cash flow that will support investments in future growth opportunities in the field of women’s health, including business development such as the recent acquisition of Alydia Health, a medical device company focused on postpartum hemorrhage. Additionally, Organon is seeking collaboration opportunities with biopharmaceutical innovators who seek to commercialize their products by leveraging Organon’s scale and presence in rapidly growing international markets.

Organon has a global presence with significant scale and geographic reach, world-class business capabilities and approximately 9,000 employees headquartered in Jersey City, New Jersey.

Organon’s forward-looking statement

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations regarding Organon’s future prospects. Forward-looking statements may be identified by words such as “objectives”, “potential”, “expects”, “intends”, “plans”, “plans”, “believes”, “seeks”, ” esteem “,” “or words with similar meanings. These statements are based on the current beliefs and expectations of the management of Organon and are subject to significant risks and uncertainties. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.

Risks and uncertainties include, but are not limited to, difficulties in developing and maintaining relationships with commercial counterparties, general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the current COVID-19 pandemic and the emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; Organon’s ability to accurately predict future results and financial performance; Organon’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Organon’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.

Organon assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors which could cause results to differ materially from those described in forward-looking statements can be found in the documents filed by Organon with the Securities and Exchange Commission (“SEC”), including its registration statement on Form 10, available on the SEC website. (

Leave A Reply

Your email address will not be published.